|
1
|
Khanna C and Hunter K: Modeling metastasis
in vivo. Carcinogenesis. 26:513–523. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pienta KJ, AbateShen C, Agus DB, Attar RM,
Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, et
al: The current state of preclinical prostate cancer animal models.
Prostate. 68:629–639. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Begley CG and Ellis LM: Drug development:
Raise standards for preclinical cancer research. Nature.
483:531–533. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valkenburg KC and Williams BO: Mouse
models of prostate cancer. Prostate cancer. 2011:8952382011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Frese KK and Tuveson DA: Maximizing mouse
cancer models. Nat Rev Cancer. 7:645–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jeet V, Russell PJ and Khatri A: Modeling
prostate cancer: A perspective on transgenic mouse models. Cancer
Metastasis Rev. 29:123–142. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bastide C, Bagnis C, Mannoni P, Hassoun J
and Bladou F: A Nod Scid mouse model to study human prostate
cancer. Prostate Cancer Prostatic Dis. 5:311–315. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Y, Xue H, Cutz JC, Bayani J, Mawji
NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, et al: An
orthotopic metastatic prostate cancer model in SCID mice via
grafting of a transplantable human prostate tumor line. Lab Invest.
85:1392–1404. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shultz LD, Schweitzer PA, Christianson SW,
Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV,
Greiner DL, et al: Multiple defects in innate and adaptive
immunologic function in NOD/LtSz-scid mice. J Immunol. 154:180–191.
1995.PubMed/NCBI
|
|
10
|
Shultz LD, Lyons BL, Burzenski LM, Gott B,
Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, et al:
Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R
gamma null mice engrafted with mobilized human hemopoietic stem
cells. J Immunol. 174:6477–6489. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Havens AM, Pedersen EA, Shiozawa Y, Ying
C, Jung Y, Sun Y, Neeley C, Wang J, Mehra R, Keller ET, et al: An
in vivo mouse model for human prostate cancer metastasis.
Neoplasia. 10:371–380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kolostova K, Pinterova D, Hoffman RM and
Bobek V: Circulating human prostate cancer cells from an orthotopic
mouse model rapidly captured by immunomagnetic beads and imaged by
GFP expression. Anticancer Res. 31:1535–1539. 2011.PubMed/NCBI
|
|
13
|
Valkenburg KC and Williams BO: Mouse
models of prostate cancer. Prostate Cancer. 2011:8952382011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berquin IM, Min Y, Wu R, Wu H and Chen YQ:
Expression signature of the mouse prostate. J Biol Chem.
280:36442–36451. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
RoyBurman P, Wu H, Powell WC, Hagenkord J
and Cohen MB: Genetically defined mouse models that mimic natural
aspects of human prostate cancer development. Endocr Relat Cancer.
11:225–254. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao H, Ouyang X, BanachPetrosky WA, Gerald
WL, Shen MM and Abate-Shen C: Combinatorial activities of Akt and
B-Raf/Erk signaling in a mouse model of androgen-independent
prostate cancer. Proc Natl Acad Sci USA. 103:14477–14482. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sano D and Myers JN: Xenograft models of
head and neck cancers. Head Neck Oncol. 1:322009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Loi M, Di Paolo D, Becherini P, Zorzoli A,
Perri P, Carosio R, Cilli M, Ribatti D, Brignole C, Pagnan G, et
al: The use of the orthotopic model to validate antivascular
therapies for cancer. Int J Dev Biol. 55:547–555. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Laird AK: Dynamics of Tumor Growth. Br J
Cancer. 13:490–502. 1964. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Herman AB, Savage VM and West GB: A
quantitative theory of solid tumor growth, metabolic rate and
vascularization. PLoS One. 6:e229732011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brawn P: Histologic features of metastatic
prostate cancer. Hum Pathol. 23:267–272. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bryden AA, Freemont AJ, Clarke NW and
George NJ: Paradoxical expression of E-cadherin in prostatic bone
metastases. BJU Int. 84:1032–1034. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Humphrey PA: Gleason grading and
prognostic factors in carcinoma of the prostate. Mod Pathol.
17:292–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
World Cancer Report 2008. World Health
Organization; Geneva: pp. 450–452. 2008
|
|
25
|
Geiger TR and Peeper DS: Metastasis
mechanisms. Biochim Biophys Acta. 1796:293–308. 2009.PubMed/NCBI
|
|
26
|
AguirreGhiso JA: Models, mechanisms and
clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bobek V, Hoffman RM and Kolostova K:
Site-specific cytomorphology of disseminated PC-3 prostate cancer
cells visualized in vivo with fluorescent proteins. Diagn
Cytopathol. 41:413–417. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Giancotti FG: Mechanisms governing
metastatic dormancy and reactivation. Cell. 155:750–764. 2013.
View Article : Google Scholar : PubMed/NCBI
|
